Conditions: Pancreatic Neuroendocrine Tumors
Keywords: Neuroendocrine tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Sunitinib
Intervention descriptions: intervention 1: Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)

Protocol document: